Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

 Industry Insights Seminar Series, debut seminar Wednesday 4 December then 1st Tuesday of the month through 2020. Sponsored by BioEscalator, hosted by MSD Business Development & Partnering Team


To view and register for all seminars click below

register button yellow

Hosted by the Business Development and Partnering team and sponsored by the BioEscalator the Industry Insights Seminar Series will kick off on Wednesday 4 December and then continue in the new year on the first Tuesday of every month. Select industry speakers will provide seminars scientific in nature across a range of medical or health topics, which will be followed by lunch and a networking opportunity.

Speakers will be encouraged to bring along colleagues to enhance the networking opportunity and one to one meetings can be facilitated upon request. This is an opportunity to, not only attend a scientific seminar of interest, but also to network with industry scientists. Seminars will be suitable for all academics with some knowledge or interest in each topic area, from PhD students to PIs. Although mostly aimed at an academic audience, those located in the BioEscalator and Wood Centre with an interest as well as local spinouts are welcome.   

  • Limited spaces available so please register for the event(s) of your interest below
  • Kicks off on Wednesday 4 December 2019 and then in 2020 the first Tuesday of every month
  • @ BioEscalator, ORC, ground floor, 12.00 -1.30 pm
  • Lunch included!
  • Networking & 1:1 meeting opportunities 
  • Questions?


Have an industry partner you would like to invite to speak? - Contact us!


Seminar Schedule: 12.00-1.30 pm @ BioEscalator, ORC


4 December 19 - Silence Therapeutics 

7 January 20 - Perspectum Diagnostics

4 February 20 - Sensyne Health

3 March 20- GE Healthcare 

7 April 20 - Isansys  

5 May 20 - GSK

WEDNESDAY 4 December 2019 - When less is more: a new twist to Galnac-conjugated sirna for treatment of liver-related disorders (Click to register)

Company: Silence Therapeutics

Marie Silence T

Presenter: Dr Marie Wikstrom Lindholm - VP Head of Technology Innovation 

Bio:Marie joined Silence Therapeutics in December 2017 as Head of Innovation Technology (now Molecular Design), leading a skilled team focusing on fine-tuning design of GalNAc-conjugated siRNA and exploring extra-hepatocyte siRNA targeting. Before that, she got >10y experience with LNA oligonucleotide research at Santaris Pharma (now Roche Innovation Centre Copenhagen). Marie has authored >50 patents and scientific publications, many in the fields of oligonucleotide drug design, safety, and function.

Abstract: Silence Therapeutics explores different options for fine tuning of GalNAc-conjugated siRNA design. Areas of special interest include siRNA modification patterns, end stabilisation, linker chemistry, and the number and location of GalNAc units. One in house discovery is that two single GalNAc units, positioned a distance apart on the sense strand, demonstrated increased activity and duration of action in wild type mice for a tool compound targeting TTR, compared to a “traditional” GalNAc triantennary design of the same siRNA sequence. At day 27 after single injection the novel design resulted in 85% reduction of target serum protein, compared to 36% reduction by equimolar amount of the control molecule. This design, as part of a molecule design toolbox, is being validated for novel siRNA GalNAc conjugates that may eventually be used as therapeutic options in liver-centric disease. We are also optimistic that the same design/synthesis principle will be useful when designing siRNA conjugates for extra-hepatic purposes.



7th January 2020 - Utility of non-invasive image derived biomarkers to characterise health and disease: Advances towards personalised medicine (Click to register)

Company: Perspectum Diagnostics Ltd

 Andera D Perspectum IISS

Presenter: Dr Andrea Dennis - Head of Biomarker Sciences

Bio: Working primarily as a biomarker scientist, Andrea works closely with the data to explore and report on the diagnostic accuracy of our data, and to examine biomarker utility for screening and enriching clinical trials. Prior to joining PD Andrea was a Post-Doctoral researcher at the Nuffield Department of Clinical Neurosciences, and a Junior Research Fellows at Linacre College, Oxford University, working on a variety of projects utilising advanced MRI to explore changes in brain structure and function in disease and rehabilitation.  



4 February 2020 - What disease? – do we have the right approach to disease classification and how this should impact our approach to treatment (Click to REGISTER)

Company: Sensyne Health 

 Rabia Sensyne Health


Presenter: Dr Rabia Khan - Chief of Translational Medicine 

Bio: Rabia has a background in immuno-genetics with a passion for bridging the worlds of science, business and technology. She completed her BSc in Biology and Economics from McGill University in Montreal, Canada and went on to complete a PhD in Genetics studying the genetics underlying the host immune response to Typhoid.

Following this, she joined Meta, an artificial intelligence company using NLP to uncover knowledge within the biomedical literature. In her role as VP Commercial Partnerships, she worked with the CEO to understand product-market fit, built products for commercial partners and was instrumental in the IAPRA partnership. Meta has since been acquired by Chan Zuckerberg BioHub.

Following Meta, she went on to a post-doctoral fellowship at the Francis Crick Institute under Dr. Frickel, where she worked on establishing cellular models for the immune response to Toxoplasma infection in induced pluripotent stem cell derived macrophages. She returned to working at the intersection of Biology and Technology and joined BenevolentAI, an AI-enabled drug discovery company, as a scientist and established a number of pre-clinical drug-discovery programmes. She worked closely with the BenevolentAI product team to define product vision based on drug-discovery needs and rose to the role of Associate Director Strategy and Planning working closely with Prof. Jackie Hunter.



3 March 2020 - Deep learning based image enhancement in positron emission tomography (click to register)

Company: GE Healthcare

Aby M GE HC for IISS

Presenter: Dr Abolfazl Mehranian - Imaging Scientist 

Bio: For the last 8 years, Abi has been involved in developing advanced model-based image reconstruction and data correction techniques in PET and (f)MRI imaging. He graduated in radiological sciences and medical physics in 2015 from University of Geneva before joining King’s College London as post-doctoral researcher for developing multi-modal synergistic reconstruction algorithms. In 2019, he was selected as the researcher of the year at School of Biomedical Engineering at King’s and was awarded the IEEE Medical Imaging Young Investigator Award. At GE Healthcare, he is involved in developing deep-learning based image enhancement and reconstruction models and AI-aided diagnostic tools for PET imaging.



7 April 2020 - Safety in numbers - next generation patient monitoring and data analysis in acute care (Click to register)

Company: Isansys 

 Keith Isansys speaker

Presenter: Keith Errey, CEO

Bio: Keith Errey is the CEO and co-founder of Isansys. Before Isansys he was the CEO and co-founder of Toumaz (London AIM TMZ) and is a strong advocate of digital and data driven methods in healthcare.

A serial entrepreneur with a long practical interest in technology businesses that originate from translational research, he was a founder of an early spin-out from Oxford University, Oxford Lasers Ltd. He then set up Oxford Synergetics Ltd, a technology transfer and facilitation consultancy where he developed a number of tools and methods for identifying and auditing technologies and developments most likely to succeed. He has wide experience in several industries including mining, telecommunications, instrumentation and medical devices, and a life-long commitment to education, having worked both as a school teacher and university lecturer.

He has physics degrees from Oxford University and the University of New South Wales.



5 May 2020 - (Registration not yet open)

Company: GSK




On this page